AR and prostate carcinoma: Triptolide inhibits the binding of RNA polymerase II, TFIIH, and AR to the target enhancer, resulting in an increased responsiveness of metastatic castration-resistant prostate cancer cells (mCRPCs) and xenograft models to enzalutamide treatment [174].